• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经退行性变中的汇聚性病理:阿尔茨海默病和帕金森病中α-突触核蛋白与 Tau 蛋白之间的机制相互作用

Converging pathologies in neurodegeneration: the mechanistic interplay between α-Synuclein and Tau in Alzheimer's and Parkinson's.

作者信息

Jeyabalan Jeyaram Bharathi, Pandi A Vignesh, Veintramuthu Sankar, Sivasamy Ramasamy, Dhanasekaran Muralikrishnan, Justin Antony

机构信息

Department of Pharmacology, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, 643 001, Tamilnadu, India.

Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, 641004, Tamil Nadu, India.

出版信息

Neurol Sci. 2025 Aug 26. doi: 10.1007/s10072-025-08421-2.

DOI:10.1007/s10072-025-08421-2
PMID:40856744
Abstract

Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative disorders globally, each characterized by distinct pathological hallmarks; primarily tau neurofibrillary tangles and amyloid-beta plaques in AD, and alpha-synuclein (α-Syn) Lewy bodies in PD. However, evidence suggests a complex interplay between these proteins, particularly α-Syn and tau, which may contribute to the progression of both diseases. Recent observations demonstrate the co-occurrence of α-Syn and tau pathologies in both AD and PD patients. At the molecular level, both proteins exhibit prion-like propagation properties and can undergo cross-seeding, where one misfolded protein species induces the misfolding, aggregation of the other and increasing neurotoxicity. These proteins also share common post-translational modifications, cellular clearance mechanisms, and are influenced by similar microenvironmental factors that favor protein aggregation. This review explores the potential mechanisms by which α-Syn in PD may influence tau pathology, potentially exacerbating AD like disease progression that may potentially contribute to cognitive decline in PD. This review also delves into the underlying molecular pathways, such as prion-like propagation, cross-seeding, and inflammatory responses that could mediate this interaction, leading to enhanced neurodegeneration in comorbid cases. Further, various clinical implications of proteins' interplay, relevance to mixed neurodegenerative phenotypes, and potential therapeutic strategies targeting both α-Syn and tau pathologies have also been discussed in this manuscript.

摘要

阿尔茨海默病和帕金森病是全球最常见的神经退行性疾病,每种疾病都有独特的病理特征;在阿尔茨海默病中主要是tau神经原纤维缠结和β-淀粉样蛋白斑块,而在帕金森病中是α-突触核蛋白(α-Syn)路易小体。然而,有证据表明这些蛋白质之间存在复杂的相互作用,特别是α-Syn和tau,这可能导致两种疾病的进展。最近的观察表明,α-Syn和tau病理在阿尔茨海默病和帕金森病患者中同时出现。在分子水平上,这两种蛋白质都表现出朊病毒样的传播特性,并且可以进行交叉播种,即一种错误折叠的蛋白质物种诱导另一种蛋白质错误折叠、聚集并增加神经毒性。这些蛋白质还具有共同的翻译后修饰、细胞清除机制,并受到有利于蛋白质聚集的类似微环境因素的影响。本综述探讨了帕金森病中的α-Syn可能影响tau病理的潜在机制,这可能会加剧类似阿尔茨海默病的疾病进展,进而可能导致帕金森病患者的认知衰退。本综述还深入研究了潜在的分子途径,如朊病毒样传播、交叉播种和炎症反应,这些途径可能介导这种相互作用,导致合并病例中神经退行性变加剧。此外,本文还讨论了蛋白质相互作用的各种临床意义、与混合神经退行性表型的相关性以及针对α-Syn和tau病理的潜在治疗策略。

相似文献

1
Converging pathologies in neurodegeneration: the mechanistic interplay between α-Synuclein and Tau in Alzheimer's and Parkinson's.神经退行性变中的汇聚性病理:阿尔茨海默病和帕金森病中α-突触核蛋白与 Tau 蛋白之间的机制相互作用
Neurol Sci. 2025 Aug 26. doi: 10.1007/s10072-025-08421-2.
2
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.组织因子及其在帕金森病中的脑脊液蛋白谱。
J Parkinsons Dis. 2024;14(7):1405-1416. doi: 10.3233/JPD-240115.
3
Unravelling the Proteinopathic Engagement of α-Synuclein, Tau, and Amyloid Beta in Parkinson's Disease: Mitochondrial Collapse as a Pivotal Driver of Neurodegeneration.揭示帕金森病中α-突触核蛋白、 Tau蛋白和β-淀粉样蛋白的蛋白病关联:线粒体崩溃作为神经退行性变的关键驱动因素
Neurochem Res. 2025 Apr 16;50(3):145. doi: 10.1007/s11064-025-04399-7.
4
Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion.与阿尔茨海默病表型及轻度认知障碍向阿尔茨海默病转化相关的不同脑脊液α-突触核蛋白聚集谱。
J Prev Alzheimers Dis. 2025 Feb;12(2):100040. doi: 10.1016/j.tjpad.2024.100040. Epub 2025 Jan 3.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease.错误折叠之谜:α-突触核蛋白与帕金森病的发病机制。
Neurochem Int. 2024 Jul;177:105760. doi: 10.1016/j.neuint.2024.105760. Epub 2024 May 7.
7
LRP1 at the crossroads of Parkinson's and Alzheimer's: Divergent roles in α-synuclein and amyloid pathology.LRP1处于帕金森病和阿尔茨海默病的交叉点:在α-突触核蛋白和淀粉样蛋白病理学中的不同作用。
Eur J Pharmacol. 2025 Sep 5;1002:177830. doi: 10.1016/j.ejphar.2025.177830. Epub 2025 Jun 6.
8
Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns.阿尔茨海默病、帕金森病和路易体痴呆中的自身抗体谱:在疾病特异性病理模式下,针对α-突触核蛋白、淀粉样β蛋白和tau蛋白的IgG亲和力改变以及IgG/IgM/IgA反应
J Neuroinflammation. 2024 Dec 3;21(1):317. doi: 10.1186/s12974-024-03293-3.
9
Structural basis of a distinct α-synuclein strain that promotes tau inclusion in neurons.一种促进神经元中tau蛋白聚集的独特α-突触核蛋白毒株的结构基础。
J Biol Chem. 2025 Apr;301(4):108351. doi: 10.1016/j.jbc.2025.108351. Epub 2025 Feb 25.
10
A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson's disease.一种靶向淀粉样前体蛋白(APP)的剪接转换反义寡核苷酸可减少帕金森病小鼠模型中α-突触核蛋白的积累。
Alzheimers Dement (N Y). 2025 Jun 23;11(2):e70117. doi: 10.1002/trc2.70117. eCollection 2025 Apr-Jun.

本文引用的文献

1
α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies.α-突触核蛋白与tau蛋白:相互作用、交叉播种以及将突触核蛋白病重新定义为复杂蛋白质病
Front Neurosci. 2025 Mar 27;19:1570553. doi: 10.3389/fnins.2025.1570553. eCollection 2025.
2
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases.错误折叠的蛋白质寡聚物:形成机制、细胞毒性作用以及针对蛋白质错误折叠疾病的药理学方法。
Mol Neurodegener. 2024 Feb 20;19(1):20. doi: 10.1186/s13024-023-00651-2.
3
Nigrostriatal tau pathology in parkinsonism and Parkinson's disease.
黑质纹状体tau 病理学在帕金森病和帕金森综合征中的作用。
Brain. 2024 Feb 1;147(2):444-457. doi: 10.1093/brain/awad388.
4
Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches.阿尔茨海默病:蛋白质在发病机制、作用机制和新治疗方法中的作用。
Neurosci Lett. 2023 Nov 20;817:137532. doi: 10.1016/j.neulet.2023.137532. Epub 2023 Oct 20.
5
Pathological and physiological functional cross-talks of α-synuclein and tau in the central nervous system.α-突触核蛋白与tau蛋白在中枢神经系统中的病理与生理功能相互作用
Neural Regen Res. 2024 Apr;19(4):855-862. doi: 10.4103/1673-5374.382231.
6
The 'α-synucleinopathy syndicate': multiple system atrophy and Parkinson's disease.“α-突触核蛋白病联盟”:多系统萎缩与帕金森病。
J Neural Transm (Vienna). 2024 Jun;131(6):585-595. doi: 10.1007/s00702-023-02653-2. Epub 2023 May 25.
7
Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain.阿尔茨海默病中的突触寡聚tau - 通过大脑传播 tau 病理学的潜在罪魁祸首。
Neuron. 2023 Jul 19;111(14):2170-2183.e6. doi: 10.1016/j.neuron.2023.04.020. Epub 2023 May 15.
8
Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis.帕金森病中的 Tau 蛋白正电子发射断层扫描成像:系统评价与荟萃分析。
Front Neurol. 2023 Apr 27;14:1145939. doi: 10.3389/fneur.2023.1145939. eCollection 2023.
9
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.帕金森病和其他突触核蛋白病中的阿尔法-突触核蛋白:从明显的神经退行性变回到早期突触功能障碍。
Cell Death Dis. 2023 Mar 1;14(3):176. doi: 10.1038/s41419-023-05672-9.
10
Alzheimer's and Parkinson's disease therapies in the clinic.临床中的阿尔茨海默病和帕金森病疗法。
Bioeng Transl Med. 2022 Aug 3;8(1):e10367. doi: 10.1002/btm2.10367. eCollection 2023 Jan.